Zacks: Analysts Expect Orthofix International NV (OFIX) Will Announce Earnings of $0.36 Per Share

Share on StockTwits

Brokerages expect Orthofix International NV (NASDAQ:OFIX) to announce $0.36 earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Orthofix International’s earnings, with estimates ranging from $0.35 to $0.36. Orthofix International reported earnings of $0.42 per share in the same quarter last year, which suggests a negative year-over-year growth rate of 14.3%. The business is expected to report its next earnings report on Monday, August 6th.

According to Zacks, analysts expect that Orthofix International will report full-year earnings of $1.66 per share for the current financial year, with EPS estimates ranging from $1.66 to $1.67. For the next fiscal year, analysts forecast that the firm will post earnings of $1.94 per share, with EPS estimates ranging from $1.88 to $2.01. Zacks’ earnings per share averages are an average based on a survey of research firms that that provide coverage for Orthofix International.

Orthofix International (NASDAQ:OFIX) last announced its quarterly earnings data on Monday, April 30th. The medical device company reported $0.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.36 by $0.03. Orthofix International had a return on equity of 11.08% and a net margin of 3.21%. The firm had revenue of $108.71 million during the quarter, compared to analysts’ expectations of $107.10 million. During the same period last year, the business posted $0.27 earnings per share. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year.

Several research analysts have recently issued reports on the company. TheStreet upgraded Orthofix International from a “c+” rating to a “b” rating in a research note on Tuesday, March 20th. BidaskClub upgraded Orthofix International from a “hold” rating to a “buy” rating in a research note on Friday, March 16th. SunTrust Banks raised their price objective on Orthofix International to $67.00 and gave the stock a “buy” rating in a research note on Monday, March 5th. ValuEngine upgraded Orthofix International from a “hold” rating to a “buy” rating in a research note on Thursday, March 1st. Finally, Gabelli restated a “buy” rating on shares of Orthofix International in a research note on Wednesday, February 28th. One research analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. Orthofix International has an average rating of “Buy” and a consensus price target of $58.07.

Shares of Orthofix International traded up $0.51, hitting $58.63, during trading on Friday, Marketbeat Ratings reports. The stock had a trading volume of 129,800 shares, compared to its average volume of 140,384. Orthofix International has a 12-month low of $42.68 and a 12-month high of $61.86. The stock has a market cap of $1.06 billion, a price-to-earnings ratio of 35.87, a PEG ratio of 3.50 and a beta of 0.26.

In related news, Director Ronald A. Matricaria purchased 10,000 shares of Orthofix International stock in a transaction that occurred on Thursday, May 3rd. The stock was bought at an average cost of $51.97 per share, for a total transaction of $519,700.00. Following the completion of the transaction, the director now owns 101,613 shares in the company, valued at $5,280,827.61. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 5.60% of the stock is currently owned by company insiders.

A number of hedge funds have recently made changes to their positions in OFIX. SG Americas Securities LLC purchased a new position in Orthofix International during the first quarter valued at approximately $151,000. Meeder Asset Management Inc. raised its position in Orthofix International by 186.4% during the first quarter. Meeder Asset Management Inc. now owns 2,626 shares of the medical device company’s stock valued at $154,000 after acquiring an additional 1,709 shares in the last quarter. Quantbot Technologies LP purchased a new position in Orthofix International during the first quarter valued at approximately $161,000. Ramsey Quantitative Systems purchased a new position in Orthofix International during the fourth quarter valued at approximately $247,000. Finally, Suntrust Banks Inc. purchased a new position in Orthofix International during the first quarter valued at approximately $256,000. Institutional investors own 91.78% of the company’s stock.

Orthofix International Company Profile

Orthofix International N.V., a medical device company, provides musculoskeletal healing products and value-added services worldwide. It operates through four segments: BioStim, Extremity Fixation, Spine Fixation, and Biologics. The BioStim segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion and are indicated as treatment to enhance fusion success rates in cervical and lumbar spine, as well as a therapeutic treatment for non-spine fractures.

Get a free copy of the Zacks research report on Orthofix International (OFIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Orthofix International (NASDAQ:OFIX)

Receive News & Ratings for Orthofix International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Axiom Price Reaches $0.0078 on Exchanges
Axiom Price Reaches $0.0078 on Exchanges
Starta Hits 24-Hour Trading Volume of $0.00
Starta Hits 24-Hour Trading Volume of $0.00
Zacks: Brokerages Expect MTS Systems Co.  Will Announce Earnings of $0.63 Per Share
Zacks: Brokerages Expect MTS Systems Co. Will Announce Earnings of $0.63 Per Share
Obalon Therapeutics  Getting Somewhat Positive Media Coverage, Study Shows
Obalon Therapeutics Getting Somewhat Positive Media Coverage, Study Shows
Novus Therapeutics  Receives News Impact Score of 0.16
Novus Therapeutics Receives News Impact Score of 0.16
$4.68 Earnings Per Share Expected for Regeneron Pharmaceuticals Inc  This Quarter
$4.68 Earnings Per Share Expected for Regeneron Pharmaceuticals Inc This Quarter


Leave a Reply

 
© 2006-2018 Zolmax.